5.305

6.94% 0.335

Arbutus Biopharma Corp (ABUS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arbutus Biopharma Corp stock is traded at $5.305, with a volume of 2.02M. It is up +6.94% in the last 24 hours and up +25.06% over the past month. Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Previous Close:

$4.97

Open:

$4.98

24h Volume:

2.02M

Relative Volume:

1.03

Market Cap:

$1.05B

Revenue:

$191.45M

Net Income/Loss:

$160.72M

P/E Ratio:

6.4498

EPS:

0.8225

Net Cash Flow:

$-34.44M

1W Performance:

+10.73%

1M Performance:

+25.06%

6M Performance:

+8.91%

1Y Performance:

+69.27%

1-Day Range:

$4.965

$5.32

1-Week Range:

$4.625

$5.32

52-Week Range:

$3.08

$5.32

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name

Arbutus Biopharma Corp

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

604-419-3200

Address

701 VETERANS CIRCLE, WARMINSTER, PA

Employee

Twitter

@arbutusbio

Next Earnings Date

2026-08-05

Latest SEC Filings

ABUS's Discussions on Twitter

Compare ABUS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABUS Arbutus Biopharma Corp	5.315	962.01M	191.45M	160.72M	-34.44M	0.8225
VRTX Vertex Pharmaceuticals Inc	523.95	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	673.01	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	925.26	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.14	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	192.60	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Initiated	Jefferies	Hold
Dec-17-20	Initiated	H.C. Wainwright	Buy
Jul-27-20	Resumed	JMP Securities	Mkt Outperform
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-20-20	Initiated	Robert W. Baird	Outperform
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Oct-07-19	Reiterated	B. Riley FBR	Buy
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral
Oct-12-18	Reiterated	Chardan Capital Markets	Buy
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Mar-19-18	Resumed	Chardan Capital Markets	Buy
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy
Feb-01-17	Reiterated	Wedbush	Outperform
Dec-13-16	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-30-16	Upgrade	Chardan Capital Markets	Neutral → Buy

View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

Jul 02, 2026

ABUS Stock Price, Quote & Chart - ChartMill

Jul 02, 2026

Jun 25, 2026